News

AMD
FDA approves Izervay for treatment of geographic atrophy
The Food and Drug Administration (FDA) recently announced their approval of Izervay for treatment of geographic atrophy (GA) secondary to age-related macular degeneration.

anti-VEGF
New anti-VEGF therapy shows promise in Phase 1 Clinical trial
The new drug is manufactured by 4D Molecular Therapeutics and is a dual-transgene intravitreal gene therapy.

AMD
AI algorithm may be a helpful tool for determining progression of AMD
Artificial intelligence may be the key in helping doctors determine which patients with intermediate AMD are at a high risk of the disease progressing to geographic atrophy.

age-related macular degeneration
Anti-VEGF treatment for wet AMD may hasten progression of glaucoma
Researchers concluded that anti-VEGF treatments do raise the risk of glaucoma progression.

AMD
One neovascular AMD treatment more effective than the other
A recent study reveals that one anti-VEGF treatment is more effective than another commonly used treatment.

AMD
Eye implant to treat wet macular degeneration approved by FDA
The device is the size of a grain of rice and is refilled every six months.

age-related macular degeneration
Study indicates some patients may be "weaned" off injections for wet macular degeneration
Study results offer hope to patients with wet macular degeneration who are receiving anti-VEGF injections.

age-related macular degeneration
Gene Therapy for Macular Degeneration positive results
For patients suffering from age-related macular degeneration, gene therapy has the potential to transfigure the treatment options that are available.

lucentis
No more monthly injections for wet macular degeneration?
The FDA just approved ranibizumab (Lucentis) as an ocular implant to be injected into the eye for people with wet macular degeneration, based upon the successful Archway study run under the FDA umb...
